Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + MEK inhibitor
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenalidomide + MEK inhibitor is a combination therapy consisting of lenalidomide, an immunomodulatory agent, and a MEK inhibitor (such as trametinib). Lenalidomide acts by modulating the immune system and directly inhibiting tumor cell proliferation through induction of apoptosis. MEK inhibitors target the mitogen-activated protein kinase (MAPK) pathway by inhibiting the activity of mitogen-activated protein kinase kinase (MEK), thereby blocking downstream signaling involved in cell growth and survival. This combination has been reported in case studies to show efficacy in treatment-resistant conditions such as xanthoma disseminatum, where both agents may act synergistically to suppress disease progression[1][2][3].
- Other names
- 雷纳度胺联合MEK抑制剂
02
Targets
MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)CRBN (Cereblon)
Beyond the preview
Go deeper on lenalidomide + MEK inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + MEK inhibitor.